Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,797.90-31.5
Stock Analysis, IPO, Mutual Funds, Bonds & More

Strides Pharma Science Ltd.

AllNewsAnnouncementRecos

BSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Strides Pharma Science Ltd.

52-Wk:

Strides Pharma Science Ltd.

Bid:

()

Offer:

()

NSE LIVE

Change:

Volume:

Open:

Prv. Close:

Today:

Strides Pharma Science Ltd.

52-Wk:

Strides Pharma Science Ltd.

Bid:

()

Offer:

()

Strides Pharma Science Outcome Of National Company Law Tribunal Convened Meeting Of Equity Shareholders Of The Company And Disclosure Under SEB...

| Announcement

Outcome of National Company Law Tribunal convened meeting of equity shareholders of the Company and disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Arvind Sharma

Strides will significantly expand its niche offerings on its front-end, which has grown multi-fold to attain a quarterly revenue size of USD 66 million.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides to acquire 18 ANDAs from Pharmaceutics International, Inc.

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 05, 2020 for Pronomz Ventures LLP & Karuna Business Solutions LLP

Strides Pharma Science Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

| Announcement

We wish to inform you the Company will be interacting with Investors/Analysts today, January 31, 2020 at Mumbai for a business update and also to take them through the financial performance for the quarter ended December 31, 2019. We would be uploading the presentation proposed to be made to the Investors/ Analysts on the occasion on Companys website at www.strides.com. You are requested to take the above information on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Scheme of Arrangement

| Announcement

Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The consolidated income of the company increased to Rs 744.66 crore in the Oct-Dec period.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

| Announcement

The Board of Directors of the Company in their meeting held today i.e., January 30, 2020 have allotted 12,638 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2015 and Strides ESOP 2016. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid-up share capital of the Company has increased from Rs. 89,55,28,260 divided into 8,95,52,826 equity shares of Rs. 10/- each to Rs. 89,56,54,640/- divided into 8,95,65,464 equity shares of Rs. 10/- each.

Strides Pharma Science Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended...

| Announcement

We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and nine months ended December 31, 2019, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 08:00 hrs and concluded at 09:00 hrs. This is for your information and record.

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 B C MAMATHA

Strides Pharma Science Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

| Announcement

Earnings Call for a discussion of un-audited financial results for the quarter and nine months ended December 31, 2019

Strides Pharma Science Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

This has reference to our letter dated January 23, 2020 relating to intimation of Board Meeting scheduled to be held on Thursday, January 30, 2020 to consider and approve inter alia unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2019. In compliance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, please find enclosed copies of newspaper advertisements published in Business Standard (English Edition) and Lokmat (Marathi Edition), both dated January 24, 2020. This is for your information and records.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides announces the successful completion of US FDA inspection at its Alathur facility with Zero 483 observations"

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA tentative approval for Triamcinolone Acetonide Ointment

Strides Pharma Science Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 (1) Of SEBI Listing Regulations

| Announcement

Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2020 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, January 30, 2020 to consider and approve inter alia unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2019. Further, as per the provisions of the Companys Code for Prevention of Insider Trading, trading window for designated persons of the Company is already closed from Wednesday, January 1, 2020 to Sunday, February 2, 2020 (both days inclusive). This is for your kind information and record purposes.

Strides Pharma Science Shareholding for the Period Ended December 31, 2019

| Announcement

Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly <a href="http://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=532531&qtrid=104.00">Click here</a>

Strides Pharma Science Statement Of Investor Complaints For The Quarter Ended December 2019

| Announcement

<table border=1><tr bgcolor=#d6d6d6><th class=TTRow-left> No.of Investor complaints pending at the beginning of the quarter </th><th class=TTRow> No.of Investor complaints received during the quarter</th><th class=TTRow> No.of Investor complaints disposed of during the quarter </th><th class=TTRow> No.of Investor complaints unresolved at the end of the quarter </th></tr><tr><td class=TTRow>0</td><td class=TTRow>26</td><td class=TTRow>26</td><td class=TTRow>0</td></tr></table><table border=1><tr><td > <span style=font-weight:bold>Name of the Signatory </span> </td><td> :- </td><td>Manjula Ramamurthy</td></tr><tr><td ><span style=font-weight:bold>Designation </span></td><td> :- </td><td>Company Secretary and Compliance Officer</td></tr></table>

Strides Pharma Science Announcement under Regulation 30 (LODR)-Newspaper Publication

| Announcement

Newspaper Advertisement of National Company Law Tribunal convened meeting of Equity Shareholders of the Company

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States

Strides Pharma Science National Company Law Tribunal Convened Meeting Of Equity Shareholders Of The Company To Be Held On February 20, 2020

| Announcement

National Company Law Tribunal convened meeting of Equity Shareholders of the Company to be held on February 20, 2020

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA approval for Loratadine OTC Softgel Capsules

Strides Pharma Science Disclosure Under Regulation 30 (5) Of The SEBI Listing Regulations

| Announcement

We wish to inform you that Dr. R Ananthanarayanan, Chief Executive Officer and Managing Director of the Company, is also appointed as Key Managerial Personnel of the Company effective January 9, 2020. Accordingly, in terms of SEBI Listing Regulations, he is also authorized to determine materiality of an event or information and to make disclosures to Stock Exchanges as required under the said Regulation. Particulars of Dr. R Ananthanarayanan is as under: Name : Dr. R Ananthanarayanan Designation : Chief Executive Officer& Managing Director Date of Appointment : January 9, 2020 Email id : investors@strides.com Phone : +91 80 6784 0335 Request you to kindly take the above on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Change in Directorate

| Announcement

This is to inform you that the Board of Directors of the Company in their meeting held today have approved the following: 1) Appointment of Dr. R Ananthanarayanan (DIN: 02231540) as Chief Executive Officer & Managing Director of the Company effective January 9, 2020, for a period of 5 years, subject to approval of the Members of the Company. Further, he is also appointed as Key Managerial Personnel of the Company effective January 9, 2020. Disclosure under Regulation 30 of the SEBI Listing Regulations for the said appointment is enclosed as Annexure. 2) Re-designation of Mr. Arun Kumar (DIN: 00084845) as Executive Director effective January 9, 2020. Request you to kindly take the above on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Please find attached Press Release issued by the Company titled: Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 V K CHACKO/ KUTTIYAMMA CHACKO

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 03, 2019 for Pronomz Ventures LLP

Strides Pharma Science Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 03, 2019 for Pronomz Ventures LLP

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Deepak Bahulal Shah

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 24, 2019 for Pronomz Ventures LLP

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

E V Manjula

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 JHONSON V SAMUEL

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 16, 2019 for Devendra Estates LLP

Strides Pharma Science Announcement under Regulation 30 (LODR)-Change in Directorate

| Announcement

This is to inform you that the Board of Directors of the Company by way of circular resolution have appointed Dr. Kausalya Santhanam (DIN: 06999168) as Independent Director of the Company. Dr. Kausalya appointment is for a period of 5 years w.e.f December 11, 2019, subject to approval of the Members of the Company. Enclosed is the disclosure under Regulation 30 of the SEBI LODR for the said appointment.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

| Announcement

Pursuant to the above-mentioned Regulations, we wish to inform you that Strides is hosting an Investor/Analyst Day on Thursday, December 5, 2019 to showcase its Biotech division Stelis Biopharma. The meet will be held at the Companys Greenfield Biotech facility in Bangalore and will be attended by a few Analysts and Investors. We would be uploading the presentations proposed to be made to the Investors/ Analysts on the occasion on Companys website at www.strides.com. You are requested to take the above information on record.

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA tentative approval for Diclofenac Potassium Softgel Capsules

Strides Pharma Science Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Announcement

Strides receives USFDA tentative approval for Diclofenac Potassium Softgel Capsules

Strides Pharma Science Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

| Announcement

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 28, 2019 for Shasun Leasing And Finance (P) Ltd and Devendra Estates Pvt Ltd

Strides Pharma Science Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

| Announcement

Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 B SREENIVASA REDDY

Strides Pharma Science Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

| Announcement

Strides Pharma Science Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly <a href="https://www.bseindia.com/stock-share-price/meetings/voting-results/532531"> Click here</a>

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service